MedDay Boosts its Research Capabilities with Profi

MedDay Boosts its Research Capabilities with Profilomic Acquisition

~Acquisition of Profilomic SA health division fuels the growth of MedDay~

Paris, France, 6 March 2017 - MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces it has boosted its research platform by acquiring the health division of Profilomic SA ("Profilomic"), an innovative company formed out of Commissariat à l'Energie Atomique (CEA) in 2010. Today's acquisition will allow MedDay to significantly strengthen its existing metabolomics research platform, SPECMET, with the aim of expanding its pipeline of neurological disorder therapies in areas of high unmet medical need.

Under the terms of the acquisition, MedDay has acquired all of the health-related assets from Profilomic, including an extensive database and laboratory equipment alongside a team of highly skilled scientists with world-class expertise in the field of metabolomics and lipidomics. SPECMET was developed in collaboration with the CEA and this acquisition will further strengthen the existing partnership and the research platform will remain close to its scientific origins at the CEA. Financial terms are undisclosed.

The MedDay SPECMET platform supports the discovery of additional pipeline assets by identifying new therapeutic targets through metabolomics analysis of cerebrospinal fluid (CSF). SPECMET screens CSF from patients with various Central Nervous System (CNS) disorders to identify the disrupted metabolic pathways. Compounds that are known to affect these metabolic pathways are then identified and further developed. New data from the platform has shown that this approach is able to identify metabolic pathway alterations in some neurological disorders where no suitable therapy is currently available ¹ . Based on the metabolic signatures identified by SPECMET in some neurological conditions, development targets can progress into preclinical studies and, if successful, have the potential to move rapidly into clinical development.  

Commenting on the acquisition, Frédéric Sedel, Chief Executive Officer of MedDay, said : "Tackling unmet medical need in central nervous system disorders by acting on brain metabolism is the driving force behind MedDay. With the acquisition of Profilomic, we have significantly expanded our research capabilities and are excited to expand our pipeline. We fully intend to identify more opportunities to expand further and will continue to invest in our pipeline through future corporate developments."

"MedDay is moving towards its goal of building a fully integrated biotechnology company, operating from discovery through to commercialization."

Reference ¹ Weiss N, et al. Cerebrosprinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy J Hepatol.  2016 Dec;65(6):1120-1130. doi: 10.1016/j.jhep.2016.07.046. Epub 2016 Aug 9

- Ends -

About MedDay MedDay is a privately held biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer); and Guillaume Brion, MD (Chief Operating Officer). The Company's most advanced pipeline candidate is MD1003 for the treatment of primary and secondary progressive multiple sclerosis. MedDay is well funded by investors including Sofinnova Partners, InnoBio, Edmond de Rothschild Investment Partners and Bpifrance Large Venture. For more information, please see: www.medday-pharma.com . Follow us on Twitter @MedDay Pharma

About Profilomic SA Profilomic is an innovative company offering a wide range of services in chemical, lipidomic and metabolomic analyses using liquid chromatography coupled to high resolution mass spectrometry (LC-HRMS). Through in-house and public databases, their software and dedicated statistical analysis tools, Profilomic can meet all requests for biomarker discovery and characterization of small organic molecules in the health, environment and food areas. Profilomic performs experiments on recent LC-MS instruments such as Q-Exactive(TM) (Thermo Scientific). Profilomic is a spin off from the Commissariat à l'Energie Atomique (CEA) created in 2010 and belonged to the  FIRALIS Group since 2015. For more information, please see: http://www.profilomic.com/en/.

For more information, please contact:

MedDay Pharmaceuticals Email: contact@medday-pharma.com

Consilium Strategic Communications Mary-Jane Elliott, Jonathan Birt, Laura Thornton, Melissa Gardiner Tel: +44 (0)20 3709 5700 Email: medday@consilium-comms.co m